What is the FLCH index?
FLCH tracks a market-cap-weighted index of large- and midcap companies in China. FLCH offers representative coverage of the Chinese equity market. As with any fund providing exposure to Chinese equities, it is important to consider which shares are being used.
What Chinese stocks does FLCH invest in?
As such, FLCH provides exposure to Chinese large- and midcap stocks as represented by H-Shares, B-Shares, and A-shares as well as N-Shares, Red-Chips, P-Chips and S-Chips.
What does FLCH track in China?
*Unless otherwise stated, data provided by FactSet. FLCH tracks a market-cap-weighted index of large- and midcap companies in China. FLCH offers representative coverage of the Chinese equity market. As with any fund providing exposure to Chinese equities, it is important to consider which shares are being used.
Which Chinese equities does FLCH provide exposure to?
As with any fund providing exposure to Chinese equities, it is important to consider which shares are being used. As such, FLCH provides exposure to Chinese large- and midcap stocks as represented by H-Shares, B-Shares, and A-shares as well as N-Shares, Red-Chips, P-Chips and S-Chips.
What is Finch Therapeutics?
What is the CP101 trial?
How long does it take for a PRISM-EXT Phase 2 to cure?
How much is Finch cash in 2021?
What is the Vickers top buyer and seller report?
What is fair value in accounting?
When will Finch stock close?
See more
About this website
FNCH Stock Price | Finch Therapeutics Group Inc. Stock Quote (U.S ...
FNCH | Complete Finch Therapeutics Group Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Finch Therapeutics Group Stock Forecast, Price & News
3.0 News and Social Media Coverage. News Sentiment Finch Therapeutics Group has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news).
Top Stock Gainers Today - Yahoo Finance
See the list of the top gaining stocks today, including share price change and percentage, trading volume, intraday highs and lows, and day charts.
vTv Therapeutics Inc. (VTVT) Stock Price, News, Quote & History - Yahoo ...
Find the latest vTv Therapeutics Inc. (VTVT) stock quote, history, news and other vital information to help you with your stock trading and investing.
How has Franklin FTSE China ETF's stock been impacted by Coronavirus?
Franklin FTSE China ETF's stock was trading at $23.2890 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FLCH shares have increased by 5.9% and is now trading at $24.66. View which stocks have been most impacted by COVID-19.
Is Franklin FTSE China ETF a good dividend stock?
Franklin FTSE China ETF pays an annual dividend of $0.37 per share and currently has a dividend yield of 1.46%. View Franklin FTSE China ETF's dividend history.
What is Franklin FTSE China ETF's stock symbol?
Franklin FTSE China ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "FLCH."
Who are Franklin FTSE China ETF's major shareholders?
Franklin FTSE China ETF's stock is owned by many different institutional and retail investors.
Which major investors are selling Franklin FTSE China ETF stock?
FLCH stock was sold by a variety of institutional investors in the last quarter, including Brandywine Oak Private Wealth LLC, Kovitz Investment Group Partners LLC, and Bank of America Corp DE.
Which major investors are buying Franklin FTSE China ETF stock?
FLCH stock was acquired by a variety of institutional investors in the last quarter, including Glovista Investments LLC, OLD Mission Capital LLC, PFG Private Wealth Management LLC, Morningstar Investment Services LLC, SOL Capital Management CO, and National Bank of Canada FI.
How do I buy shares of Franklin FTSE China ETF?
Shares of FLCH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is Finch Therapeutics?
(“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 2:45 pm ET. A live webcast will be available under the ‘Investors & News’ section of the Finch website. A replay of the webcast will become available approximately three hours after the event and will be archived for approximately 30 days. About Finch Therapeutics Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively. Media Contact:Gabriella [email protected] Contact:Greg [email protected]
What is the CP101 trial?
In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI.
How long does it take for a PRISM-EXT Phase 2 to cure?
New data from 132-participant PRISM-EXT Phase 2 open-label trial show 80.3% sustained clinical cure rate through 8 weeks , with a similar rate maintained through 24 weeks and a safety profile consistent with previously reported dataAggregated 88.2% sustained clinical cure rate shown through 8 weeks following last dose in post-hoc analysis of participants that received up to two doses of CP101 in PRISM3 and PRISM-EXT trialsFinch also announces start of enrollment in PRISM4 Phase 3 trial SOMERVILLE
How much is Finch cash in 2021?
The increase was primarily due to increased headcount to support Finch’s operational growth and an increase in professional fees to support Finch’s transition to a public company.Finch’s cash and cash equivalents as of March 31, 2021 was $193.0 million compared to $99.7 million as of December 31, 2020.
What is the Vickers top buyer and seller report?
Daily – Vickers Top Buyers & Sellers for 03/26/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
What is fair value in accounting?
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
When will Finch stock close?
The offering is expected to close on March 23, 2021, subject to customary closing conditions.
What is Finch Therapeutics?
(“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 2:45 pm ET. A live webcast will be available under the ‘Investors & News’ section of the Finch website. A replay of the webcast will become available approximately three hours after the event and will be archived for approximately 30 days. About Finch Therapeutics Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively. Media Contact:Gabriella [email protected] Contact:Greg [email protected]
What is the CP101 trial?
In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI.
How long does it take for a PRISM-EXT Phase 2 to cure?
New data from 132-participant PRISM-EXT Phase 2 open-label trial show 80.3% sustained clinical cure rate through 8 weeks , with a similar rate maintained through 24 weeks and a safety profile consistent with previously reported dataAggregated 88.2% sustained clinical cure rate shown through 8 weeks following last dose in post-hoc analysis of participants that received up to two doses of CP101 in PRISM3 and PRISM-EXT trialsFinch also announces start of enrollment in PRISM4 Phase 3 trial SOMERVILLE
How much is Finch cash in 2021?
The increase was primarily due to increased headcount to support Finch’s operational growth and an increase in professional fees to support Finch’s transition to a public company.Finch’s cash and cash equivalents as of March 31, 2021 was $193.0 million compared to $99.7 million as of December 31, 2020.
What is the Vickers top buyer and seller report?
Daily – Vickers Top Buyers & Sellers for 03/26/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
What is fair value in accounting?
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
When will Finch stock close?
The offering is expected to close on March 23, 2021, subject to customary closing conditions.
